Effects of progesterone on the growth regulation in classical progesterone receptor-negative malignant melanoma cells.
This study investigated the growth-regulating effects of progesterone (Prog) on nPR-negative malignant melanoma cells and the possible mechanisms. A375 and A875 cells were cultured and treated with Prog of different concentrations. For signal transduction pathway studies, the cells were pretreated with Prog receptor antagonist (RU486, 1 x 10(-7) mol/L) or MAPK inhibitor (U0126, 5 x 10(-6) mol/L) for 1 h and then co-incubated with prog (10(-9) mol/L) for another 24 h. Indirect immunofluorescence assay, MTT, flow cytometry and Western blotting were used for assessing the nPR expression, cell growth, cell apoptosis and ERK1/2 Phosphorylation, respectively. Our results showed that lower progesterone concentration promoted the proliferation of both A375 and A875 cells, but this growth-stimulatory effect decreased at progesterone concentration of 1 x 10(-7) mol/L or higher. The response could be abolished by MAPK inhibitor U0126, but could not be blocked by progesterone antagonist RU486. Flow cytometry exhibited that high concentration ([Symbol: see text]1 x 10(-7) mol/L) progesterone increased the apoptosis of the two cells in a dose-dependent manner. The level of ERK1/2 phosphorylation was increased by a lower progesterone concentration, but reduced by a higher concentration (1 x 10(-6) mol/L). These results suggest progesterone exerts growth-regulating effects on nPR-negative tumor cells through a non-genomic mechanism.
Fang
Xianfeng
X
Department of Dermatology, Affiliated Ruikang Hospital, Guangxi University of Traditional Chinese Medicine, Nanning, 530011, China. fxf007@21cn.com
Zhang
Xuxin
X
Zhou
Meng
M
Li
Jiawen
J
D002070:Butadienes / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D008545:Melanoma / Q000378:metabolism / Q000473:pathology*; D015735:Mifepristone / Q000494:pharmacology; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors; D009570:Nitriles / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology*; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects*; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology
D002070:Butadienes; D009570:Nitriles; D011980:Receptors, Progesterone; C113580:U 0126; D015735:Mifepristone; D011374:Progesterone; D020929:Mitogen-Activated Protein Kinase Kinases
Endocr Rev. 1997 Aug;18(4):502-19
9267762
Steroids. 2008 Oct;73(11):1160-73
18603275
Trends Endocrinol Metab. 1998 Dec;9(10):419-27
18406316
Steroids. 2008 Jan;73(1):116-28
18037150
Front Neuroendocrinol. 2008 May;29(2):292-312
18343488
Climacteric. 2004 Jun;7(2):129-37
15497901
Mol Endocrinol. 2007 Jun;21(6):1335-58
17440047
Steroids. 2008 Aug;73(7):738-50
18395237
Steroids. 2008 Oct;73(9-10):953-60
18249430
Hum Reprod Update. 2009 Jan-Feb;15(1):119-38
18936037
Obstet Gynecol Surv. 2002 Feb;57(2):112-9
11832787
J Immunol. 2002 Feb 1;168(3):1087-94
11801642
Vet J. 2008 Jun;176(3):265-6
17855132
Semin Surg Oncol. 1996 Nov-Dec;12(6):402-6
8914204
Steroids. 2003 Nov;68(10-13):761-70
14667966
J Biol Chem. 2002 Feb 15;277(7):5209-18
11717311
J Invest Dermatol. 2001 Aug;117(2):274-83
11511305
J Biol Chem. 2003 Oct 10;278(41):39261-4
12893816
J Huazhong Univ Sci Technolog Med Sci. 2008 Apr;28(2):216-8
18481002
Brain Res Bull. 2009 Aug 14;79(6):426-30
19477244
J Steroid Biochem Mol Biol. 2009 May;115(1-2):36-43
19429459
J Invest Dermatol. 2007 Sep;127(9):2207-15
17508026
Reproduction. 2004 Aug;128(2):139-46
15280552
Mol Cell Biol. 2000 May;20(9):3102-15
10757795
Tohoku J Exp Med. 2007 May;212(1):1-12
17464097
Int J Biochem Cell Biol. 2006 Feb;38(2):288-96
16233985